|
MRPS22 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.626032641866E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.3504757008559E-14 |
| Normal-vs-Stage2 |
5.822600E-03 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
1.296070E-02 |
| Stage1-vs-Stage3 |
1.205830E-02 |
| Stage1-vs-Stage4 |
1.880500E-03 |
| Stage2-vs-Stage3 |
2.963800E-04 |
| Stage2-vs-Stage4 |
7.68090000000665E-05 |
| Stage3-vs-Stage4 |
4.544400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.46690000005323E-06 |
| Normal-vs-Asian |
5.11820000048679E-07 |
| Caucasian-vs-AfricanAmerican |
3.777200E-01 |
| Caucasian-vs-Asian |
2.853800E-02 |
| AfricanAmerican-vs-Asian |
5.375400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.55431223447522E-15 |
| Normal-vs-Female |
1.7581491817964E-12 |
| Male-vs-Female |
1.900210E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.20001794559721E-12 |
| Normal-vs-Age(41-60Yrs) |
1.64057656348859E-12 |
| Normal-vs-Age(61-80Yrs) |
1.2646994562715E-11 |
| Normal-vs-Age(81-100Yrs) |
2.47159999999802E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.192000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.396800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.950000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.397800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.396400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.110400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.337850E-02 |
| Classical-VS-Follicular |
9.76950000000087E-05 |
| Classical-VS-Other |
7.971200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
6.34229999962876E-07 |
| Tall-VS-Other |
3.207800E-01 |
| Tall-VS-Normal |
1.77746706242488E-12 |
| Follicular-VS-Other |
1.563950E-01 |
| Follicular-VS-Normal |
3.806200E-04 |
| Other-VS-Normal |
3.834500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.59280366673897E-11 |
| Normal-vs-N1 |
1.95399252334028E-14 |
| N0-vs-N1 |
5.035600E-03 |
|
|
